Lakefront Biotherapeutics N.V. (LKFT) Stock Score, Valuation & Financial Research

Lakefront Biotherapeutics N.V. is in the Healthcare sector and Biotechnology industry. It is reviewed using Wall Street Score's company-strength, valuation, growth and financial-health framework. A complete Wall Street Score is not currently available.

Quick answer for LKFT

Lakefront Biotherapeutics N.V. does not currently have a complete Wall Street Score. The stored market price is USD 29.32. These figures are a research snapshot, not a buy or sell recommendation.

What Lakefront Biotherapeutics N.V. does

Lakefront Biotherapeutics NV, formerly Galapagos NV, is a biotechnology company that focuses on transforming patient outcomes through scientific innovation. It is dedicated to building a pipeline of medicines for patients with serious diseases in therapeutic areas of unmet need, prioritizing oncology and immunology & inflammation programs. The company's clinical-stage portfolio is anchored by potential first-in-class treatments for autoimmune diseases.

Company business and revenue

Research reporting period: 2025-12-31. A research update is not a new financial filing.

How the company makes money

Lakefront Biotherapeutics is a biotechnology company that generates revenue primarily through research and development collaborations, licensing agreements for its proprietary drug candidates, and product sales. The company focuses on discovering and developing small molecule and antibody therapies in the fields of immunology and oncology, often partnering with larger pharmaceutical entities to fund clinical trials and commercialize its pipeline.

Products and services

  • The company's pipeline includes GLPG3667 for inflammatory diseases, GLPG5101 and GLPG5301 as CAR-T cell therapy candidates for oncology, and various other small molecule and antibody programs.

Customer types

Pharmaceutical and biotechnology companies; Healthcare providers and research institutions.

Suppliers, materials and equipment

  • Contract Research Organizations (CROs) — Various unnamed third-party organizations providing clinical trial management and research support services. Source
  • Contract Manufacturing Organizations (CMOs) — Unnamed third-party manufacturers responsible for the production of clinical trial materials and drug candidates. Source

Business relationships and partnerships

  • Gilead Sciences — A long-standing strategic collaboration involving the development and commercialization of various pipeline assets and research programs. Source

Competitors and product-market comparisons

  • AbbVie — Competes in the immunology and inflammatory disease therapeutic markets. Source
  • Bristol Myers Squibb — Competes in the oncology and CAR-T cell therapy development space. Source
  • Novartis — Competes in the development of advanced cell therapies and oncology treatments. Source

Business strengths to evaluate

  • Robust proprietary drug discovery platform Source
  • Strong cash position to support R&D activities Source

Business risks and research considerations

  • Dependence on strategic partners for commercialization and funding Source
  • Inherent risks and uncertainties in clinical trial outcomes and regulatory approvals Source

Sources: Company research source · Gilead Sciences

Company research refreshed 2026-10-12. This is saved research, not a live check of company relationships. Check the reporting period and source disclosures. Financial figures and scores follow their separate update schedules.

LKFT financial snapshot

Statement amounts: USD. Quote amounts: USD. No exchange-rate conversion is performed in this snapshot. Market-capitalization currency is not supplied by this projection.

Wall Street Score:
Not currently available
Stored price:
USD 29.32
Market capitalization:
1.93B (currency not supplied)
Revenue:
USD 1.12B
Net income:
USD 676.6M
Free cash flow:
USD -307.68M
Cash:
USD 154.11M
Total debt:
USD 7.21M
EPS:
USD 10.26
P/E ratio:
2.9x

What stands out

  • Reported year-over-year revenue growth is -10.9%.
  • Free cash flow is USD -307.68M, negative for the stored period.
  • The balance sheet shows USD 154.11M of cash versus USD 7.21M of total debt, an excess of cash over debt on these two reported measures.
  • The current research record carries a fundamental change risk warning, which should be reviewed alongside the score.

Company-specific financial comparisons

The following are calculated from saved company data, not forecasts or statements about future performance. Differences in reporting dates or units can make a ratio misleading; verify the original filings.

  • Free cash flow is -27.4% of stored revenue. This is a simple cross-field ratio, not a verified same-period cash conversion margin; confirm reporting periods before comparison.
  • Net income equals 60.2% of stored revenue. This is an indicative ratio only; accounting periods and units should be verified in filings.
  • Cash exceeds debt by USD 146.9M using the stored balance-sheet values. This does not include other obligations or restricted cash.

Questions worth answering for LKFT

Use these questions to check the stored figures against the latest company filings. They identify issues to investigate; they are not findings about management's plans or future results.

  • What is driving LKFT's revenue decline, and does the latest filing suggest the weakness is temporary or structural?
  • How long can LKFT fund negative free cash flow using its current cash position before it may need more debt or new shares?
  • How is LKFT likely to use its cash advantage: reinvestment, acquisitions, debt reduction, dividends or buybacks?
  • What does the current fundamental change risk warning mean for the reliability or interpretation of LKFT's score?

What the numbers mean

A complete valuation score is not currently available, so valuation should be checked using the available earnings, cash-flow and price data.

A complete financial score is not currently available, so investors should review cash, debt, earnings and cash flow directly.

A strong company and an attractive stock price are not always the same thing. Revenue, earnings, free cash flow, debt, management quality, competitive advantage and valuation should be considered together. Wall Street Score organizes these inputs into a consistent research framework so investors can identify what deserves deeper review.

Data freshness: Financial data last refreshed 2026-10-01.

Research-input completeness: 82% of the scoring inputs required for this public page are currently available.

How to research LKFT

Start by understanding how the company makes money. Then compare revenue and earnings trends, cash generation, debt, liquidity and valuation. Review the company's latest filings and earnings reports before acting on any score or model estimate.

Learn how to analyze a stock · Read the Wall Street Score methodology · Browse other stocks

Data may change as company filings and market prices update. Educational research only; not a buy or sell recommendation.